Nicotinic Acetylcholine Receptor alpha 4 (CHRNA4) Human shRNA Plasmid Kit (Locus ID 1137)
CAT#: TG313920
CHRNA4 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector, 5µg of each construct provided
Need custom shRNA service?
Get a free quote
CNY 4,790.00
货期*
现货
规格
Cited in 1 publication. |
Product images
经常一起买 (2)
Specifications
Product Data | |
Product Name | Nicotinic Acetylcholine Receptor alpha 4 (CHRNA4) Human shRNA Plasmid Kit (Locus ID 1137) |
Locus ID | 1137 |
UniProt ID | P43681 |
Synonyms | BFNC; EBN; EBN1; NACHR; NACHRA4; NACRA4 |
Vector | pGFP-V-RS |
Format | Retroviral plasmids |
Kit Components | CHRNA4 - Human, 4 unique 29mer shRNA constructs in retroviral GFP vector(Gene ID = 1137). 5µg purified plasmid DNA per construct29-mer scrambled shRNA cassette in pGFP-V-RS Vector, TR30013, included for free. |
RefSeq | NM_000744, NM_001256573, NR_046317, NM_000744.1, NM_000744.2, NM_000744.3, NM_000744.4, NM_000744.5, NM_000744.6, NM_001256573.1, BC096290, BC096291, BC096292, BC096293, BM710937, NM_001256573.2 |
Summary | This gene encodes a nicotinic acetylcholine receptor, which belongs to a superfamily of ligand-gated ion channels that play a role in fast signal transmission at synapses. These pentameric receptors can bind acetylcholine, which causes an extensive change in conformation that leads to the opening of an ion-conducting channel across the plasma membrane. This protein is an integral membrane receptor subunit that can interact with either nAChR beta-2 or nAChR beta-4 to form a functional receptor. Mutations in this gene cause nocturnal frontal lobe epilepsy type 1. Polymorphisms in this gene that provide protection against nicotine addiction have been described. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Feb 2012] |
shRNA Design | These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service. |
Performance Guaranteed | OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples. For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred). |
Citations (1)
The use of this RNAi has been cited in the following citations: |
---|
Mechanisms of tumor-promoting activities of nicotine in lung cancer: synergistic effects of cell membrane and mitochondrial nicotinic acetylcholine receptors
,Chernyavsky, AI;Shchepotin, IB;Galitovkiy, V;,
BMC Cancer
[CHRNA4]
|
Documents
Product Manuals |
FAQs |
SDS |
Customer
Reviews
Loading...